Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study

Conclusions: One-year efficacy, supported by functional improvements and favorable safety and tolerability profiles, supports further investigation of erenumab as a preventive treatment in patients with EM. Clinicaltrials.gov identifier: NCT01952574. Classification of evidence: This study provides Class IV evidence that for patients with episodic migraine, erenumab reduces long-term MMD and improves headache-related disability and migraine-specific quality of life.

http://www.neurology.org/cgi/content/short/89/12/1237?rss=1

Source: Neurology - September 18, 2017 Category: Neurology Authors: Ashina, M., Dodick, D., Goadsby, P. J., Reuter, U., Silberstein, S., Zhang, F., Gage, J. R., Cheng, S., Mikol, D. D., Lenz, R. A. Tags: Migraine, All Clinical trials, Class IV ARTICLE Source Type: research